Moderna has announced that its Phase 3 trial of mRNA-1083, an investigational combination influenza vaccine and COVID-19, met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial.

mRNA-1083 comprises components of mRNA-1010, Moderna's seasonal influenza vaccine candidate, and mRNA-1283, Moderna's next-generation COVID-19 vaccine candidate. Each investigational vaccine has independently demonstrated positive Phase 3 clinical trial results.

The current Phase 3 clinical trial ( Identifier:NCT06097273) is a randomized, observer-blinded, active control study evaluating the safety, reactogenicity and immunogenicity of mRNA-1083 in two independent cohorts of approximately 4,000 adults each.

''Combination vaccines have the potential to reduce the burden of respiratory viruses on healthcare systems and pharmacies, as well as offer people more convenient vaccination options that could improve compliance and provide better protection against seasonal illnesses,'' said Stéphane Bancel, president and CEO of Moderna.

Moderna is the only company with a positive Phase 3 combination vaccine against influenza and COVID. Building on the momentum of positive Phase 3 data across our respiratory portfolio, we continue to address important unmet medical needs and advance public health."

Copyright (c) 2024 All rights reserved.